Click on headlines below to download research

Defining data from lead assets by year-end
Transgene | 27/03/2019

Key inflection points from lead assets Pexa-Vec, TG4010 and TG4001 by year-end will continue to inform the validity of Transgene’s IO strategy. Notably,…

TG4010 and Pexa-Vec readouts to define 2019
Transgene | 30/11/2018

Late-stage clinical trial readouts in 2019 will be critical to Transgene’s immunoncology (IO) aspirations and, if positive, could further its position…

Combination strategy awaiting validation
Transgene | 19/11/2018

Transgene develops virus-based product candidates for use in oncology and infectious diseases. Its five clinical products are currently in seven clinical…